References
Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the reninangiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645-651.
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82: 1730-1736.
Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71: 3A-11A.
Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259-1265.
Pitt B, Zannad F, Remme WJ, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
The effect of eplerenone on wound healing, ventricular remodeling, and infarct expansion following myocardial infarction. G.D. Searle&Co., Document No. BRD99D 973; 23 June 1999.
A dose-ranging study of eplerenone versus placebo and spironolactone in patients with symptomatic heart failure. G.D. Searle & Co., Protocol No. IE3-97-02-011, 21 May 1997.
Efficacy and safety evaluation of a range of doses of SC-66110 in the treatment of mild to moderate hypertension. G.D. Searle&Co., Protocol No. EE3-96-02-010; Report No. EE3-99-06-010, 08 January 1999.
Investigational brochure for eplerenone (SC-66110) selective aldosterone receptor antagonist (SARA), Edition 5. G.D. Searle & Co., Document No. NE3-99-21-900, 11 August 1999.
de Gasparo M, Joss U, Ramjoue HP. Three new epoxyspironolactone derivatives: Characterization in vivoand in vitro.J Pharmacol Exp Ther 1987; 240: 650-656.
Effect of rat plasma on in vitro binding affinity of SC-66110 and spironolactone for the mineralocorticoid receptor. G.D. Searle & Co., Document No. BRD97 D 861, 10 August 2000.
Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. JACC 2000; 35(5): 1245-1255.
Guyatt GH, Feeny DH, Patrick DL. Measuring healthrelated quality of life. Ann Intern Med 1993; 118: 622-629.
Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol 1994; 74: 1240-1244.
Ware J Jr., Kosinksi M, Keller SD. A 12-item shortform health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-233.
Jenkinson C, Layte R, Jenkinson D, et al. A shorter form health survey: Can the SF-12 replicate results from the SF-36 longitudinal studies? J Public Health Med 1997; 19: 179-186.
Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project. International Quality of Life Assessment Project. J Clin Epidemiol 1998; 51: 1171-1178.
Kind P. The EuroQoL instrument: An index of healthrelated quality of life. In: Spilker B, Ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven; 1996: 191-201.
Torrence GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5: 1-30.
Burnham MA, Wells KB, Leake B, Landsverk J. Development of a brief screening instrument for detecting depressive disorders. Med Care 1988; 26: 775-789.
Derogatis LR, Melisaratos N. The Brief Symptom Inventory: An introductory report. Psychol Med 1983; 13: 595-605.
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
Køber L, Torp-Pedersen C, Carlsen JE, et al. for the Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-1676.
Torp-Pedersen C, Køber L, Carlsen J on behalf of the TRACEStudy Group. Angiotensin-converting enzyme inhibition after myocardial infarction: The trandolapril cardiac evaluation study. Am Heart J 1996; 132: 235-243.
Hall AS, Winter C, Bogle SM, Mackintosh AF, Murray GD, Ball SG on behalf of the AIRE Study Investigators. The acute infarction ramipril efficacy (AIRE) study: Rationale, design, organization, and outcome definitions. J Cardiovasc Pharmacol 1991; 18(Suppl 2): S105-S109.
Pitt B, Perez A. for the Randomized Aldactone Evaluation Study Investigators. Letters to the editor. N Engl J Med 2000; 342: 132-134.
Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-467.
Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Controlled Clinical Trials 1995; 16: 395-407.
Spargias KS, Hall AS, Ball SG. Safety concerns about digoxin after acute myocardial infarction. Lancet 1999; 354: 391-392.
Peto R, Peto J. Asymptotically efficient rank invariant procedures. J Royal Statistical Society, Series A 1972; 135: 185-206.
Kaplan EL, Meier PL. Nonparametric estimation from incomplete observations. J Am Statistical Assoc 1958; 53: 457-481.
Cox DR. Regression models and life-tables. J Royal Statistical Society, Series B 1972; 34: 187-220.
Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663.
Smith AGE. Spironolactone in the Long-Term Management of Patients with Congestive Heart Failure. Curr Med Res Opin 1980; 7: 131-136.
Muller J. Spironolactone in the management of congestive heart failure: A review. Clin Ther 1986; 9: 63-76.
Sun Y, Ramires FJA, Wever KT. Fibrosis of Atria and Great Vessels in Response to Angiotensin II or Aldosterone Infusion. Cardiovasc Res 1997; 35: 138-147.
Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26: 671-677.
Pitt B. “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovascular Drugs and Therapy 1995; 9: 145-149.
Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995; 16(Suppl N): 103-106.
Struthers AD. Why does spironolactone improve mortality over and above and ACE inhibitor in chronic heart failure? Br J Clin Pharmacol 1999; 47: 479-482.
MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces the early morning rise in heart rate failure patients. Cardiovasc Res 1997; 35: 30-34.
Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24(5): 571-575.
Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-1376.
Weber KT, Janicki JS, Pick R, et al. Collagen in the hypertrophied pressure-overloaded myocardium. Circulation 1987; 75(Suppl I): I-40-I-47.
F. Zannad Aldosterone and Heart Failure. Eur Heart J 1995; 16(Suppl N): 98-102.
Struthers A. Aldosterone and artery compliance in heart failure. Eur Heart J 1998; 19: 1273.
Struthers AD. Aldosterone escape during angiotensinconverting enzyme inhibitor therapy in chronic heart failure. J Cardiac Failure 1996; 2(1): 47-54.
Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Mineralocorticoid antagonism reduces Ang II-induced renal injury in stroke-prone hypertensive rats. Am J Hypertension 1998; 11(Suppl): 94A.
Klug D, Robert V, Swynghedauw B. Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol 1993; 71(Suppl A): 46A-54A.
Frierdich G, Schuh J, Brown M, Nochowiak D, Blehm D, Delyani JA. Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosteroneinduced hypertension and cardiac fibrosis. Am J Hypertension 1998; 11 (Suppl): 94A.
Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during longterm angiotensin II suppression. J Endocr 1981; 91: 457-465.
Cleland JGF, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: A double blind controlled trial. Br Heart J 1984; 52: 530-535.
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736.
Hall AS, Murray GD, Ball SG on behalf of the AIREX Study Investigators. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349(9064): 1493-1497.
Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40-55.
Cleland JGF, Erhardt L, Murray F, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure: A report from the AIRE Study Investigators. Eur Heart J 1997; 18: 41-51.
Rodriguez JA, Godoy I, Castro P, Quintana JC, Chavez E, Corbalan R. A double-blind randomized placebo controlled study of ramipril vs. spironolactone on left ventricular remodeling after acute myocardial infarction. JACC 1997; abstract 947-9: 133A.
Epstein M, Menard J, Alexander JC, Roniker B. Eplerenone, a novel and selective aldosterone receptor antagonist: Effi-cacy in patients with mild to moderate hypertension. Circulation 1998; 98 (Suppl): I-98-99, Abstract 498.
The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
The EPISTENT Investigators. Randomized placebocontrolled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352: 87-92.62
The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). Am J Cardiol 1996; 78: 902-912.
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
Beta-Blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 1982; 247: 1707-1714.
ISIS I (First International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous atenolol among 16,027 cases of suspected myocardial infarction: ISIS-1. Lancet 1986; 2: 57-65.
Kjekshus J, Pedersen R, for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 64C-68C.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Am J Cardiol 1991; 68: 1436-1446
Rights and permissions
About this article
Cite this article
Pitt, B., Williams, G., Remme, W. et al. The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction. Cardiovasc Drugs Ther 15, 79–87 (2001). https://doi.org/10.1023/A:1011119003788
Issue Date:
DOI: https://doi.org/10.1023/A:1011119003788